Glenmark Launches Fixed Dose Combination Drug For Diabetes I
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Glenmark Pharmaceuticals said it has launched a fixed-dose combination drug for the treatment of Type 2 diabetes in the country. It has introduced a fixed-dose combination of Remogliflozin Etabonate and Vildagliptin in India for the management of Type 2 diabetes.

The drug contains Remogliflozin (100 mg) and Vildagliptin (50 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients. The company has launched the product under two brand names Remo V and Remozen V in the country.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed-dose combination and India is the first country to get access to this FDC drug. While the average daily cost of therapy of existing brands in the same drug category is ?78, Glenmark''s Remogliflozin-Vildagiptin combination has been launched at ?14 per tablet.


Diabetes is a key area of focus for the company and the launch of this product will enable it to improve access to diabetes treatment by providing an effective and affordable treatment option to patients in India. Globally, SGLT2 inhibitors (Sodium-Glucose Co-Transporter Inhibitor) and DPP4 inhibitors (Dipeptidyl Peptidase 4 inhibitor) are emerging as the preferred treatment option for the management of Type 2 diabetes.

Source:
https://www.thehindu.com/news/national/glenmark-launches-fixed-dose-combination-drug-for-diabetes-in-india/article33444155.ece
Dr. T●●●●z H●●●●●●i and 4 others like this4 shares
Like
Comment
Share